About US
Contact us
-
Mylan President Rajiv Malik targeted as states expand price fixing suit against top drugmakersMylan President Rajiv Malik and Emcure CEO Satish Mehta were named individually in a vastly expandedcivil lawsuitovergeneric price fixingbrought by nearly every state in the country. The price fixing2017/10/25
-
Don't count out a consumer spinoff, Pfizer execs say amid Q3 M&A grillingIn the opening remarks of Tuesday’s Q3 earnings conference call, Pfizer CEO Ian Read offered up prescription trends and launch details on the company’s key products, including cancer treatments Ibranc2017/10/25
-
Roche discount wins Tecentriq first-in-class NICE backing for bladder cancerRoche's Tecentriq first hit the market as a bladder cancer therapy last year, but new data havesincefailed to prove it can extend those patients' lives. Thatdidn't stop England's cost-effectiveness wa2017/10/24
-
Undeterred by Pfizer's looming OTC sale, Merck KGaA scouts consumer health biddersIf you thought Merck KGaA would press pause on selling its consumer healthunit until Pfizer’s was off the market, think again. The German drugmaker this week started reaching out to prospective buy2017/10/24
-
Novartis seeks Kymriah nod in lymphoma, setting up Gilead CAR-T showdownCutting-edge cell therapies from Novartis and Gilead Sciences aren't direct competitors for now, but that could change—and soon. The Swiss drugmaker's Kymriah is now up for an FDA approval in diffus2017/10/23
-
Samsung reports operating profit, extends collaboration with Merck KGaAThree years into a manufacturing collaboration, Germany’s Merck KGaA and South Korea’s Samsung BioLogics have decided to deepen their relationshipeven as Samsung reported an operating profit for the f2017/10/23
-
Veterans' lawsuit claims Big Pharma bribes in Iraq helped finance terrorismPharma companies have faced a gamut of allegations over the years, but a new lawsuit ups the ante by alleging several drugmakers paid bribes in Iraq that helped fuel terrorism. Filed Tuesday in2017/10/20
-
More pharma friends in high places? Ex-Lilly boss Alex Azar up for HHS chiefUntil January, Alex Azar was Eli Lilly's USA pharma chief, the company's top post in North America. Now he's reportedly in line for the top job at HHS, where he could help pharma navigate some turbu2017/10/20
-
Bristol-Myers' Opdivo gets into high gear for new melanoma approvalEarly, early, early. Bristol-Myers Squibb has been on a sprint with Opdivo in a new group of melanoma patients—with an early trial halt, a quick unveiling of detailed data, and now, a speedy review at2017/10/19
-
AstraZeneca's Lynparza ups the ante at the PARP table with FDA's speedy breast cancer reviewIn June, AstraZeneca revealed that in a phase 3 trial, its Lynparza had pared down the risk of disease worsening or death in breast cancer patients by 42%. And that showing apparently impressed the FD2017/10/19